Document Detail


Appraisal of various thrombolytic agents in the treatment of acute myocardial infarction.
MedLine Citation:
PMID:  3115099     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The immediate therapeutic objective after the onset of symptoms of an evolving myocardial infarction is to stop the process from progressing. Evidence has accumulated that this can be accomplished by the early dissolution of the clot within an acutely thrombosed artery, resulting in reperfusion of the ischemic area. There are five clot-dissolving agents currently being evaluated by intravenous administration for their ability to dissolve coronary thrombi and to produce clinical benefit; all are plasminogen activators and each has distinctive properties. Streptokinase, because it has been the agent most extensively studied and its clinical benefits have been established, now serves as a standard for comparison with the others (anisoylated plasminogen-streptokinase activator complex, urokinase, recombinant tissue plasminogen activator, and recombinant pro-urokinase). It is apparent that each of the agents has advantages and disadvantages and that none has established its superiority over the others as of yet.
Authors:
S Sherry
Related Documents :
6801949 - Coronary angiography during acute myocardial infarction: a search for spasm.
15576019 - Angiographic patency study of an albumin-free recombinant streptokinase formulation in ...
3312369 - Development and evaluation of anisoylated plasminogen streptokinase activator complex (...
3711489 - Elevated serum d dimer: a degradation product of cross-linked fibrin (xdp) after intrav...
10761189 - Magnesium and calcium concentration in the abdominal aorta of patients deceased by isch...
6692439 - Intraarterial infusion of low-dose streptokinase after acute thromboembolization of the...
25406899 - Adrenergic receptor genotype influences heart failure severity and β-blocker response ...
16099219 - Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues.
9633059 - Vdd pacing in persistent left superior vena cava.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of medicine     Volume:  83     ISSN:  0002-9343     ISO Abbreviation:  Am. J. Med.     Publication Date:  1987 Aug 
Date Detail:
Created Date:  1987-10-06     Completed Date:  1987-10-06     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0267200     Medline TA:  Am J Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  31-46     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anistreplase
Coronary Circulation
Coronary Vessels
Fibrinolytic Agents / administration & dosage,  therapeutic use*
Hemorrhage / chemically induced
Hemostasis / drug effects
Heparin / adverse effects
Humans
Infusions, Intravenous
Injections
Myocardial Infarction / drug therapy*,  mortality
Plasminogen / therapeutic use
Streptokinase / administration & dosage,  adverse effects,  therapeutic use
Tissue Plasminogen Activator / adverse effects,  pharmacology,  therapeutic use
Urokinase-Type Plasminogen Activator / adverse effects,  therapeutic use
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 81669-57-0/Anistreplase; 9001-91-6/Plasminogen; 9005-49-6/Heparin; EC 3.4.-/Streptokinase; EC 3.4.21.68/Tissue Plasminogen Activator; EC 3.4.21.73/Urokinase-Type Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Relevance of changes in blood fibrinolytic and coagulation parameters during thrombolytic therapy.
Next Document:  Intrafamilial variability in lysosomal storage diseases.